To combat the high prevalence of metabolic diseases worldwide, the needs for novel PPARγ agonists that feature maximum beneficial effects i.e., efficient glycemic control or enhanced “browning” effects while avoid undesirable side effects are heightened. Here, PPARG is linked to metabolic disease.